stoxline Quote Chart Rank Option Currency Glossary
  
Acumen Pharmaceuticals, Inc. (ABOS)
4.05  -0.05 (-1.22%)    03-28 16:00
Open: 4.12
High: 4.275
Volume: 510,020
  
Pre. Close: 4.1
Low: 4.012
Market Cap: 235(M)
Technical analysis
2024-03-28 4:19:03 PM
Short term     
Mid term     
Targets 6-month :  5.15 1-year :  5.94
Resists First :  4.41 Second :  5.09
Pivot price 4.15
Supports First :  3.3 Second :  2.75
MAs MA(5) :  4.09 MA(20) :  4.22
MA(100) :  3.33 MA(250) :  4.42
MACD MACD :  0 Signal :  0.1
%K %D K(14,3) :  50.9 D(3) :  45.3
RSI RSI(14): 50.6
52-week High :  11.31 Low :  1.8
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ ABOS ] has closed above bottom band by 34.2%. Bollinger Bands are 43.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 4.28 - 4.31 4.31 - 4.33
Low: 3.65 - 3.67 3.67 - 3.7
Close: 4.05 - 4.1 4.1 - 4.14
Company Description

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

Headline News

Thu, 28 Mar 2024
HC Wainwright Weighs in on Acumen Pharmaceuticals, Inc.'s Q1 2024 Earnings (NASDAQ:ABOS) - MarketBeat

Thu, 28 Mar 2024
Acumen Pharmaceuticals (ABOS) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance

Thu, 28 Mar 2024
Acumen Pharmaceuticals (NASDAQ:ABOS) Earns Buy Rating from HC Wainwright - Defense World

Thu, 28 Mar 2024
Acumen Pharmaceuticals' (ABOS) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat

Wed, 27 Mar 2024
Acumen Pharmaceuticals files for $200M mixed shelf offering (NASDAQ:ABOS) - Seeking Alpha

Wed, 27 Mar 2024
Will Acumen Pharmaceuticals Inc (ABOS) Outperform the Rest of the Stocks in the Healthcare Sector? - InvestorsObserver

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Neutral
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 58 (M)
Shares Float 30 (M)
Held by Insiders 9.4 (%)
Held by Institutions 75.1 (%)
Shares Short 773 (K)
Shares Short P.Month 732 (K)
Stock Financials
EPS -1.12
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 4.84
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -14.6 %
Return on Equity (ttm) -20.5 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.99
Qtrly Earnings Growth 0 %
Operating Cash Flow -46 (M)
Levered Free Cash Flow -31 (M)
Stock Valuations
PE Ratio -3.65
PEG Ratio -0.2
Price to Book value 0.83
Price to Sales 0
Price to Cash Flow -5.11
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android